GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » T2 Biosystems Inc (NAS:TTOO) » Definitions » Days Sales Outstanding
中文

T2 Biosystems (T2 Biosystems) Days Sales Outstanding

: 69.54 (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

T2 Biosystems's average Accounts Receivable for the three months ended in Dec. 2023 was $1.28 Mil. T2 Biosystems's Revenue for the three months ended in Dec. 2023 was $1.68 Mil. Hence, T2 Biosystems's Days Sales Outstanding for the three months ended in Dec. 2023 was 69.54.

The historical rank and industry rank for T2 Biosystems's Days Sales Outstanding or its related term are showing as below:

TTOO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.06   Med: 63.13   Max: 616.51
Current: 75.04

During the past 12 years, T2 Biosystems's highest Days Sales Outstanding was 616.51. The lowest was 31.06. And the median was 63.13.

TTOO's Days Sales Outstanding is ranked worse than
56% of 225 companies
in the Medical Diagnostics & Research industry
Industry Median: 69.24 vs TTOO: 75.04

T2 Biosystems's Days Sales Outstanding increased from Dec. 2022 (31.13) to Dec. 2023 (69.54).


T2 Biosystems Days Sales Outstanding Historical Data

The historical data trend for T2 Biosystems's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

T2 Biosystems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 100.96 79.76 66.56 59.70 90.91

T2 Biosystems Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.13 76.54 62.07 77.12 69.54

Competitive Comparison

For the Diagnostics & Research subindustry, T2 Biosystems's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


T2 Biosystems Days Sales Outstanding Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, T2 Biosystems's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where T2 Biosystems's Days Sales Outstanding falls into.



T2 Biosystems Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

T2 Biosystems's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (2.163 + 1.42) / 2 ) / 7.193*365
=1.7915 / 7.193*365
=90.91

T2 Biosystems's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (1.139 + 1.42) / 2 ) / 1.679*365 / 4
=1.2795 / 1.679*365 / 4
=69.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


T2 Biosystems  (NAS:TTOO) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


T2 Biosystems Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of T2 Biosystems's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


T2 Biosystems (T2 Biosystems) Business Description

Traded in Other Exchanges
N/A
Address
101 Hartwell Avenue, Lexington, MA, USA, 02421
T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. The company's core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease.
Executives
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund (a) L.p. 10 percent owner C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund B (cayman) L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Lev Aiv I L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Unlev Aiv I L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Michael Terrence Gibbs officer: General Counsel 12 STONEY BROOK RD., HOPKINTON MA 01748
John M Sprague officer: Chief Financial Officer 101 HARTWELL AVE., LEXINGTON MA 02421
Sperzel John J Iii director, officer: See Remarks 61 CRESTVIEW LANE, BRUNSWICK ME 04011
Brett A. Giffin officer: Chief Commercial Officer 101 HARTWELL AVE., LEXINGTON MA 02421
Alec Barclay officer: SVP, Operations 101 HARTWELL AVE., LEXINGTON MA 02421
Aparna Ahuja officer: Chief Medical Officer 101 HARTWELL AVENUE, LEXINGTON MA 02421
Laura Lee Adams director 101 HARTWELL AVE., LEXINGTON MA 02421
Anthony Pare officer: Chief Commercial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Thierry Bernard director 101 HARTWELL AVENUE, LEXINGTON MA 02421